Monitoring heparin by the activated clotting time in endovascular treatment in ruptured intracranial aneurysms: 6AP3-9

Results and discussion: Blood loss (median and interquartile range) in the control group was 8.4g [7.4-11.7g] and was increased in the placebo group 16.8g [12.1-25.2], p=0.02. In the platelet lowand intermediate dose groups, blood loss did not significantly vary as compared with the placebo group. However, high dose of platelet transfusion significantly reduced prasugrelinduced bleeding (9.1g [8.1-11.0], p=0.02), and blood loss in this group was thus similar to the control group. Regarding safety, platelet transfusion was not associated with an increase of thrombotic events, whatever the dose of platelet transfusion in this model. Conclusion(s): In this animal model, a high dose of platelet transfusion was necessary to significantly decrease prasugrel-related bleeding.